STUDY FINDINGS AND THEIR LIMITS
The evidence needs to match the treatment being claimed
Researchers had different aims for sugar, growth hormone and desire when making these medicines. Trials found benefits for certain groups. Those findings leave other uses unproven.
This independent guide helps you understand treatment claims
Researchers designed semaglutide, tirzepatide, tesamorelin and PT-141 for different body changes. Their prescription products went on to treat different health problems. Calling a medicine approved doesn't establish every proposed benefit. Your claim needs the drug, the reason for treatment and the people tested.
The large sugar and weight trials concern semaglutide and tirzepatide. These drugs copy hormones, body chemicals carrying messages that help the body respond to food. Tesamorelin increases growth hormone to reduce unusual belly fat buildup with HIV. Bremelanotide acts through the brain to treat distressing loss of desire, which is a different treatment need.
FDA Peptide Watch is an independent guide, rather than the government speaking. The published studies help you understand what was tested and what remains unknown, but the guide can't assess your own health history or choose which medicine would fit your needs. Nor does the guide help locate products or turn study details into treatment instructions.
Fair comparisons help show whether the drug made a difference
Chance can decide who receives which treatment, helping keep the groups fair. Testing both medicines together gives a more direct comparison than separate trials. A review can bring trials together, though those trials may differ. More time helps check lasting benefits; knowing the treatment can affect expectations and ratings.
Animals can help explain body actions without proving benefit for you. Trials with more people can check illnesses that happen infrequently. Trials lasting longer can reveal changes over more time. Weight loss, heart attacks, fat scans and desire ratings answer different questions, so a convincing finding still needs to match the people and illness being claimed.
Numbers in brackets point to the studies or official drug instructions. Personal accounts come from people who chose to report an experience. People trying peptides for research describe experiences that haven't been checked through a fair treatment comparison. The volunteered reports cannot be used to count everyone's risk or establish that a drug caused a change.
Benefits leave safety questions and untested uses to consider
A certain medicine's approval covers a certain reason for treatment. Tesamorelin's unusual fat problem with HIV doesn't establish ordinary weight loss. Bremelanotide's approved use before menopause doesn't cover every person's sexual concerns. Semaglutide and tirzepatide approvals can't establish what research bottles with those names contain.
Benefits may come with stomach trouble, illness of the gallbladder that stores digestive fluid, or other harm. Hormone changes, heart risks and skin darkening can matter to you too. Hamsters showed no added sign that bremelanotide made sexual activity more rewarding. That animal finding doesn't measure relief from lost desire in women.
Longer follow-up can help tell whether benefits last during treatment. People who know their drug may expect help and rate improvements differently. That makes a fair comparison harder without a group getting treatment without the drug. You need the harms and unanswered questions alongside the benefits when judging a treatment claim.